Susquehanna International Group, LLP Hepion Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.31 - $1.06 $18,235 - $62,354	58,825 Added 61.32%	154,754 $120,000
Q4 2022 Feb 14, 2023	SELL	$0.27 - $11.9 $18,700 - $824,205	-69,261 Reduced 41.93%	95,929 $28,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $10.4 $36,424 - $742,778	71,421 Added 76.17%	165,190 $84,000
Q2 2022 Aug 15, 2022	BUY	$0.57 - $1.22 $25,233 - $54,009	44,270 Added 89.44%	93,769 $54,000
Q1 2022 May 16, 2022	SELL	$0.93 - $1.29 $36,416 - $50,513	-39,158 Reduced 44.17%	49,499 $64,000
Q4 2021 Feb 14, 2022	SELL	$1.14 - $1.58 $30,204 - $41,862	-26,495 Reduced 23.01%	88,657 $101,000
Q3 2021 Nov 15, 2021	SELL	$1.39 - $2.1 $170,989 - $258,329	-123,014 Reduced 51.65%	115,152 $176,000
Q2 2021 Aug 11, 2021	SELL	$1.56 - $2.26 $180,016 - $260,792	-115,395 Reduced 32.64%	238,166 $472,000
Q1 2021 May 17, 2021	BUY	$1.77 - $2.98 $554,592 - $933,720	313,329 Added 778.81%	353,561 $651,000
Q4 2020 Feb 16, 2021	BUY	$1.58 - $3.64 $63,566 - $146,444	40,232 New	40,232 $88,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $51.8M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.